Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

Status:

NO_LONGER_AVAILABLE

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

Lead Sponsor:

Mesoblast, Inc.

Conditions:

Graft-Versus-Host Disease

Eligibility:

All Genders

18-70 years

Brief Summary

This protocol allows for the treatment of patients, male and female, between the ages of 18 years and 70 years. Patients must have failed to respond to steroid treatment for Grade C-D acute GVHD.

Detailed Description

This is a treatment protocol to provide patients who have failed steroid treatment for acute GVHD expanded access of Prochymal. It is anticipated that a maximum of 10 patients per month for a total of...

Eligibility Criteria

Inclusion

Patients must be 18 years to 70 years of age, inclusive.
Biopsy confirmation of GVHD is strongly recommended, to exclude patients presenting with diarrhea or abnormal liver function tests caused by infection.
Patients must have failed to respond to steroid treatment (methylprednisolone \[≥1mg/kg/day\] or equivalent) for Grades C-D acute GVHD.
Prochymal must be administered not longer than 14 days after the initiation of systemic steroid therapy for acute GVHD.
Prochymal must be administered either before or at the same time any additional GVHD therapy is administered
Patients must have an adequate renal function as defined by Cockcroft-Gault equation:Calculated creatinine clearance (CrCl) \> 30 mL/min
Patients who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception.

Exclusion

Patient has stage 3 or 4 liver GVHD, bilirubin \>6 mg/dl.
Patient has stage 4 GI-GVHD.
Patient has any underlying or current medical condition that would interfere with the evaluation of the patient including uncontrolled infection, sepsis, organ failure, etc or any medical condition that has a high probability of causing death in less than 30 days.
Patient may not receive any other investigational agent (not approved by the FDA for any indication) concurrently for the duration of the protocol.
Patient has evidence of a pulmonary infiltrate or diffuse alveolar hemorrhage and must not be likely to require more than 2 liters of oxygen via face mask or an estimated fractional inspired oxygen concentration (FiO2) of 28% via other delivery methods in order to sustain an O2 saturation of 92% during the next 3 days.
Patient has a known allergy to bovine or porcine products
Patient has a medical history of a solid tumor disease.

Key Trial Info

Start Date :

Trial Type :

EXPANDED_ACCESS

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00826046

Last Update

March 9 2020

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

Indiana BMT

Beech Grove, Indiana, United States, 46107

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02284